pjSS (n = 9) | sjSS (n = 6) | sJSS MCTD (n = 10) | |
---|---|---|---|
“Sicca symptoms” | n = 9 (100%) | n = 3 (50%) | n = 9 (90%) |
Glandular swelling | n = 7 (77.8%) | n = 3 (50%) | n = 5 (50%) |
Glandular pain | n = 4 (44.4%) | n = 2 (33.3%) | n = 6 (60%) |
Affected Glandulae submandibulares | n = 8 (88.8%) | n = 5 (83.3%) | n = 10 (100%) |
Renal manifestations | n = 0 | n = 1 (16.6%) | n = 0 |
Articular | n = 7 (78%) | n = 6 (100%) | n = 10 (100%) |
Peripheral nervous system | n = 1 (11.1%) | n = 0 | n = 0 |
Cutaneous | n = 5 (55.5%) | n = 5 (83.3%) | n = 6 (60%) |
Fatigue | n = 8 (88.8%) | n = 6 (100%) | n = 9 (90%) |
Fever | n = 3 (33.3%) | n = 4 (66.6%) | n = 6 (60%) |
ESSDAI (mean) | 19.2 (range 7–35) | 21.3 (range 10–44) | 24.1 (range 3–72) |
Remarkable CRP/ ESR (C-reactiv-protein/ erythrocyte sedimentation rate) | n = 8 (88.8%) | n = 4 (66.6%) | n = 4 (40%) |
anti-Ro antibody + | n = 9 (100%) | n = 4 (66.6%) | n = 1 (10%) |
anti-La antibody + | n = 8 (88.8%) | n = 4 (66.6%) | n = 0 |